Santen Pharmaceutical Co., Ltd. announced the change of Representative Director of the Board. This change was made as the Board received offer from Akira Kurokawa, Representative Director of the Board, Chairman, to resign from his position as Representative Director of the Board, effective from April 1, 2024. Takeshi Ito (Representative Director of the Board, President and Chief Executive Officer) is the only Representative Director of the Board of the Company after this change.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,530 JPY | +1.12% | +1.59% | +9.04% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.04% | 3.5B | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- 4536 Stock
- News Santen Pharmaceutical Co., Ltd.
- Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024